From GlobeNewswire:

Akoya Biosciences announced their preliminary unaudited revenue for the 4th quarter and full year of 2023. The expected revenue for the 4th quarter of 2023 is between $25.5 to $26.5 million and for the full year, it’s expected to be between $95.6 to $96.6 million. The projected year-end cash balance is expected to be between $83.0 to $85.0 million. Their CEO expressed confidence in achieving cash flow positivity sooner than anticipated. For 2024, Akoya anticipates revenue growth of 20% and projects operating cash flow breakeven by year-end. These figures remain subject to change pending final quarter-end closing and audit.



Read more: Akoya Biosciences Announces Preliminary Financial Results